Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Thomas Fenech, SOE 2019 – Updates in diabetic retinopathy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 20th 2019

Thomas Fenech (Mater Dei Hospital, Msida, Malta) shares his thoughts on the most recent developments in diabetic retinopathy and the most promising areas of research for the future.

Questions:

1. What have been the most significant recent developments in diabetic retinopathy? (0:04)
2. Discuss the current unmet needs and/or the challenges you face when treating patients. (1:20)
3. What are the most promising areas of research in your field? (2:40)
4. Which presentations/data at SOE have interested you the most? (3:40)
5. Do you have a message for young ophthalmologists in Europe? (4:50)

Filmed in partnership with the European Society of Ophthalmology (SOE) at the SOE 2019 meeting in Nice, France.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup